IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Germany

  • ID: 1408482
  • Report
  • Region: Germany
  • 50 Pages
  • IMS Health
1 of 3
The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets.

This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.
Note: Product cover images may vary from those shown
2 of 3
1. HEALTHCARE SYSTEM
Facts & Figures
Market Indicators
Provision & Funding
Statutory Health Insurance
Private Health Insurance
Healthcare Services
Healthcare Reform

2. PRICING
Prescription Drugs
Early Benefit Assessments
Rebate Negotiations Following Early Benefit Assessments
Market Developments
Mandatory Rebates
Voluntary Discount Agreements
Generic Drugs
Mandatory Discounts
Voluntary Discount Agreements
Hospital Drugs
Pricing
Purchasing
Dispensing to Out-patients
OTC Drugs
Discounts

3. REIMBURSEMENT
Admission to Reimbursement
Non-prescription Drugs
Lifestyle Drugs
Minor Illnesses
Unproven Therapeutic Benefit, Medical Necessity or Economic Efficiency
Therapeutic Recommendations
Off-label Drugs
Negative List
Reimbursement Categories
Reimbursement Prices
Reference Price System
Hospital Reimbursement
Formularies
Funding
Changes in Reimbursement Status
Changes in Reimbursement Prices
Price Moratorium
Impact of Early Benefit Assessments
Reference Price Revisions
Germany, Pharmaceutical Pricing & Reimbursement Concise Guide

4. PHARMACOECONOMICS
Pharmacoeconomic Requirements
Early Benefit Assessments
Benefit Assessments
Cost-benefit Assessments

5. PRICE BUILD UP
Wholesalers
Margins
Discounts
Direct Distribution
Unit-dose Products
Background
Retail Pharmacies
Prescription Drugs
Non-Prescription Drugs
Parallel Import Quota
Background
Dispensing Doctors
Sales Tax

6. COST CONTAINMENT
Industry Paybacks
Promotional Costs
Advertising
Payments to Physicians
Patient Co-payments
GKV
PKV
Prescribing Controls
Binding Prescribing Guidelines
Prescribing Conditions for Drugs Subject to Early Benefit Assessments
Regional Prescribing Agreements
Disease Management Programmes
Prescribing Software
Generics
Generic Substitution
Biosimilars
Rx-to-OTC Switches
Process
Recent Switches
OTC Market
Parallel Trade
Parallel Imports
Parallel Exports

7. FUTURE DEVELOPMENTS
Outlook
Germany, Pharmaceutical Pricing & Reimbursement Concise Guide
Biosimilars Savings Potential
Parallel Import Dispensing Quota Controversy

8. NAMES & ADDRESSES
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll